| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| otlertuzumab | leukocyte antigen cd37 | NA | Clinical trial target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Peripheral T-Cell Lymphoma[MeSHID:D016411] Chronic Lymphocytic Leukemia[MeSHID:D015451] |
95.48 | phase 2 | antibody |
| otlertuzumab | leukocyte antigen cd37 | NA | Clinical trial target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Peripheral T-Cell Lymphoma[MeSHID:D016411] Chronic Lymphocytic Leukemia[MeSHID:D015451] |
95.48 | phase 2 | unknown |
| click here to return to the previous page | ||||||||